The AI-powered platform elevates cardiometabolic care by extending its best-in-class weight management support to CKD and MASH.
COLUMBIA, Md.–(BUSINESS WIRE)–Welldoc®, a leading AI-powered health tech company pioneering cardiometabolic care, today announced the expansion of its platform to include comprehensive support for the management of chronic kidney disease (CKD) and metabolic dysfunction-associated steatohepatitis (MASH). This expansion reinforces Welldoc’s commitment to delivering holistic, evidence-based AI-driven solutions that address the complex, interconnected nature of cardiometabolic conditions.
Building upon its clinical foundation in cardiometabolic health, which includes weight management with and without GLP-1 medications, Welldoc now provides individuals with integrated AI-driven coaching, education and health tracking specific to CKD and MASH. This support is especially vital given the expected expansion of GLP-1 therapies for broader cardiorenal and liver protection [1,2]. By directly addressing the cardiometabolic risk factors driving these conditions, Welldoc enables early detection, engagement and proactive provider interventions.
“As an endocrinologist, I see firsthand how interconnected and frequently undiagnosed these conditions are,” said Dr. Mansur Shomali, Welldoc Chief Medical Officer and practicing endocrinologist. “Our clinical foundation and advanced AI enable us to personalize the experience so individuals and their providers can manage all of their comorbid cardiometabolic conditions in one comprehensive platform and directly address the root causes driving CKD and MASH progression.”
This strategic expansion addresses urgent challenges posed by two often silent diseases that carry significant clinical and economic burdens:
- CKD’s Hidden Crisis: Approximately 9 out of 10 people with CKD are unaware they have the condition, meaning millions miss the critical early window for intervention [3]. This lack of awareness contributes to a substantial healthcare cost, with annual Medicare spending alone exceeding $115 billion [4].
- MASH’s Growing Epidemic: Fatty liver disease affects up to two-thirds of individuals with type 2 diabetes and up to 90% of individuals with severe obesity [5]. The condition is predicted to become the leading cause of liver transplant in the United States [6]. AI-powered health tech solutions offer the opportunity to support personalized lifestyle interventions, which are the cornerstone of early management.
The platform’s robust ability to support weight management is crucial for individuals diagnosed with MASH, where lifestyle and weight loss are cornerstone treatment strategies.
“Obesity is a major driving force behind MASH progression,” said Dr. Holly Lofton, Scientific Advisor at Welldoc and Director of the Medical Weight Management Program at NYU Langone Health. “The most impactful steps an individual diagnosed with fatty liver disease can take involve lifestyle changes to achieve weight loss. By integrating MASH support into their cardiometabolic and weight platform, Welldoc is providing a highly efficient way to reinforce the insights necessary to slow the progression of liver disease.”
References:
[1] Perkovic V, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW Trial). N Engl J Med. 2024. [Semaglutide reduced the risk of the primary composite kidney and CV death outcome by 24%].
[2] Sanyal AJ, et al. Semaglutide 2.4 mg in Patients with MASH and Fibrosis Stage F2 or F3: The ESSENCE Trial. N Engl J Med. 2025 (Interim Analysis). [Semaglutide achieved resolution of MASH without worsening of fibrosis in 62.9% of the treatment group].
[3] Centers for Disease Control and Prevention. Chronic Kidney Disease in the United States, 2023. Atlanta, GA: US Dept of Health and Human Services; 2023.
[4] National Kidney Foundation. Chronic Kidney Disease Data Analysis Strategy. [Reflects annual Medicare spending for beneficiaries with CKD/Kidney Failure].
[5] National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Definition & Facts of NAFLD & NASH. [Cites studies on prevalence in T2D/Obesity].
[6] Tesfay M, Goldkamp WJ, Neuschwander-Tetri BA. NASH: the emerging most common form of chronic liver disease. Mo Med. 2018;115(3):225-229. [Citing projections that MASH would become the leading cause of liver transplant by 2030].
About Welldoc
Welldoc®, an AI powered health technology leader revolutionizing cardiometabolic care, integrates personalized, real-time, and actionable insights into the daily lives of individuals living with cardiometabolic conditions, facilitating improved health and outcomes. Welldoc’s comprehensive digital health platform provides AI-powered digital coaching across prediabetes, diabetes, hypertension, heart failure, weight and obesity management, CKD, and MASH, with integrated mental wellbeing and sleep support. As a FDA-cleared digital health solution, Welldoc guides individuals through the complex journey of living with diabetes, enabling self-management while enhancing connections with their healthcare team. The company partners with health plans, health systems and employers to extend care, improve health and reduce costs.
Welldoc has achieved 11 510(k) clearances for diabetes functionality within its digital health platform and holds an IP portfolio of 50+ patents for its advanced AI and first-in-class technology. With more than 90 clinical publications, Welldoc has built an extensive library of clinical research, including many publications focused on the value of combining CGM with AI-powered digital health solutions. Recognized as an industry thought leader, Welldoc has been featured in prestigious conferences and publications, including South by Southwest, the Wall Street Journal and the Economist. The company has been named the “Best Overall Digital Health Company” by MedTech Breakthrough for the past three years, and was a winner of the 2024 Healthcare AI Impact Awards, Innovation Awards by Business Intelligence Group, and Top 100 Healthcare Technology Companies by the Healthcare Technology Report. For more information, visit www.welldoc.com. Follow us on LinkedIn and X.
Contacts
Sylvia Aranda
Media@welldocinc.com
